Literature DB >> 15555552

The chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferon gamma.

Dick Wågsäter1, Peder S Olofsson, Lars Norgren, Björn Stenberg, Allan Sirsjö.   

Abstract

Atherosclerosis is an inflammatory disease that is characterised by the involvement of chemokines that are important for the recruitment of leukocytes and scavenger receptors that mediate foam cell formation. Several cytokines are involved in the regulation of chemokines and scavenger receptors in atherosclerosis. CXCL16 is a chemokine and scavenger receptor and found in macrophages in human atherosclerotic lesions. Using double-labelled immunohistochemistry, we identified that smooth muscle cells in human lesions express CXCL16. We then analysed the effects of IFN-gamma, TNF-alpha, IL-12, IL-15, IL-18, and LPS on CXCL16 expression in cultured aortic smooth muscle cells. IFN-gamma was the most potent CXCL16 inducer and increased mRNA, soluble form, membrane form, and total cellular levels of CXCL16. The IFN-gamma induction of CXCL16 was also associated with increased uptake of oxLDL into these cells. Taken together, smooth muscle cells express CXCL16 in atherosclerotic lesions, which may play a role in the attraction of T cells to atherosclerotic lesions and contribute to the cellular internalisation of modified LDL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15555552     DOI: 10.1016/j.bbrc.2004.10.160

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  26 in total

1.  Atherogenic lipids induce high-density lipoprotein uptake and cholesterol efflux in human macrophages by up-regulating transmembrane chemokine CXCL16 without engaging CXCL16-dependent cell adhesion.

Authors:  Jana Barlic; Wenjia Zhu; Philip M Murphy
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

Review 2.  Helper T cells and atherosclerosis: the cytokine web.

Authors:  S G Baidya; Q-T Zeng
Journal:  Postgrad Med J       Date:  2005-12       Impact factor: 2.401

3.  CXCL16 regulates cell-mediated immunity to Salmonella enterica serovar Enteritidis via promotion of gamma interferon production.

Authors:  Olivier L Fahy; Scott L Townley; Shaun R McColl
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

Review 4.  Immunological aspects of atherosclerosis.

Authors:  S Garrido-Urbani; M Meguenani; F Montecucco; B A Imhof
Journal:  Semin Immunopathol       Date:  2013-11-09       Impact factor: 9.623

Review 5.  Role of smooth muscle cells in the initiation and early progression of atherosclerosis.

Authors:  Amanda C Doran; Nahum Meller; Coleen A McNamara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-02-14       Impact factor: 8.311

6.  Accumulation of serum lipids by vascular smooth muscle cells involves a macropinocytosis-like uptake pathway and is associated with the downregulation of the ATP-binding cassette transporter A1.

Authors:  Jennifer Rivera; Anna K Walduck; Shane R Thomas; Elias N Glaros; Elizabeth U Hooker; Elizabeth Guida; Christopher G Sobey; Grant R Drummond
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-08-30       Impact factor: 3.000

Review 7.  Atherosclerosis and interferon-γ: new insights and therapeutic targets.

Authors:  Iryna Voloshyna; Michael J Littlefield; Allison B Reiss
Journal:  Trends Cardiovasc Med       Date:  2013-08-02       Impact factor: 6.677

8.  CXCL16: a chemokine-causing chronic kidney disease.

Authors:  Allison E Norlander; Mohamed A Saleh; Meena S Madhur
Journal:  Hypertension       Date:  2013-09-23       Impact factor: 10.190

Review 9.  Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity?

Authors:  Jon T Giles
Journal:  Curr Rheumatol Rep       Date:  2016-05       Impact factor: 4.592

10.  The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers.

Authors:  Merav Darash-Yahana; John W Gillespie; Stephen M Hewitt; Yun-Yun K Chen; Shin Maeda; Ilan Stein; Satya P Singh; Roble B Bedolla; Amnon Peled; Dean A Troyer; Eli Pikarsky; Michael Karin; Joshua M Farber
Journal:  PLoS One       Date:  2009-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.